- Home
- LILAK vs OGN Comparison
LILAK vs OGN Comparison
Compare LILAK & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | OGN |
|---|---|---|
| Founded | 2017 | 1923 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LILAK | OGN |
|---|---|---|
| Price | $7.96 | $7.48 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $8.20 | ★ $11.63 |
| AVG Volume (30 Days) | 726.0K | ★ 6.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | N/A | $1.65 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.23 | $6.18 |
| 52 Week High | $9.13 | $16.18 |
Technical Indicators
Market Signals| Indicator | LILAK | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 40.62 |
| Support Level | $7.76 | $6.50 |
| Resistance Level | $8.43 | $7.58 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 52.91 | 38.91 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.